Drug-Induced Movement Disorder Awareness Program.

2025-2026 Regular Session Introduced by Jeff Gonzalez and 1 co-sponsor

AB 641 would create a state public education and clinical guidance program to raise awareness, screen for, and guide treatment of drug‑induced movement disorders from antipsychotic

From committee: Filed with the Chief Clerk pursuant to Joint Rule 56.

#drug-inducedmovementdisorderawarenessprogram

Main purpose

AB 641 would require the California Department of Public Health (CDPH), subject to appropriation, to develop and administer a time‑limited public education and clinical‑guidance program to raise awareness of drug‑induced movement disorders (DIMDs) that can result from antipsychotic and related medications used to treat mental illness. The bill emphasizes screening, diagnosis, stigma reduction, and guidance for care delivered via telehealth.

Key provisions

Directs CDPH, upon appropriation of state or federal funds, to develop and administer a DIMD awareness program by a specified date (bill documents contain alternate target dates of January 1, 2027 and January 1, 2028).

Program elements must include:

Evidence‑based educational information on the importance of periodic screening for and identifying symptoms of DIMDs and known risk factors.
Development of guidance on clinical standards for treating DIMDs, including guidance applicable to telehealth services (in some bill versions).
Education and outreach aimed at eliminating stigma and bias against people living with DIMDs related to mental health treatment.

Authorizes CDPH to consult with the Department of Health Care Services and the Behavioral Health Services Oversight and Accountability Commission.

Adds new chapters to the Health and Safety Code (various section numbers included in the text).

Sunsets automatically: the bill text contains alternate repeal dates (January 1, 2031 and January 1, 2032), depending on the version.

Who is affected

Patients receiving antipsychotic or dopamine‑blocking therapies (e.g., those with schizophrenia, bipolar disorder, major depression) — particularly those at risk for conditions such as tardive dyskinesia.

Mental health and primary care providers, telehealth clinicians, public safety officials, and public health educators who would use or distribute the materials and guidance.

CDPH and partner state agencies involved in program design/implementation.

Funding, timing, and procedural notes

No dedicated funding is provided in the bill; activities occur only “upon appropriation” by the Legislature or receipt of federal funds.

The bill was amended in April 2025 and referred to Assembly Appropriations (placed on the suspense file); as of May 23, 2025 it is held under submission.

The text contains inconsistencies between versions (notably target start and sunset dates). Final implementation dates and chapter placements will depend on the enrolled/amended version if the bill advances.

Potential impact

If funded and implemented, the program could increase detection and treatment referrals for DIMDs, improve clinical practice guidance (including telehealth considerations), and reduce stigma by educating providers, patients, and the public. Impact is contingent on legislative appropriation, agency implementation choices, and whether guidance influences clinical practice or payer policies (the bill itself creates education and guidance rather than mandating clinical or payment changes).

Bill